Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.00 (0.00%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

New OPTIM Software and Hardware

4 Aug 2014 07:00

RNS Number : 0911O
Avacta Group PLC
04 August 2014
 



4 August 2014

Avacta Group plc

("Avacta" or the "Group")

 

 

New OPTIM Software and Hardware

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Avacta Analytical has completed the development of two new OPTIM variants. Alongside this, the Group has released upgraded OPTIM software, intended to widen the range of potential customers. 

OPTIM, Avacta Analytical's protein characterisation instrument, was launched during 2010 as OPTIM 1000 and was substantially redeveloped into the OPTIM2 system during 2013. Designed to reduce the time and cost of therapeutic protein development, the OPTIM instruments can provide multiple protein stability-indications at high speed using ultra-low sample volumes.

Avacta has completed the development of upgraded software for the OPTIM platform, expanding the capabilities available to end users. Two new variants to the core OPTIM platform, OPTIM 375 and OPTIM 445, which incorporate incremental measurement capabilities are now available. The Directors consider that these two new variants and the related upgraded software widen the appeal of OPTIM in its core drug development market by focusing on applications to characterise the viscosity of samples and the stability of membrane protein targets.

Alastair Smith, Avacta Group Chief Executive of Avacta said: "Now that OPTIM is becoming established as a valuable tool for protein stability characterisation, we are working hard to expand the range of applications and measurement types that the system can support in order to broaden the instrument's market appeal and drive consumable usage. The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples."

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel: +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Walbrook PR Ltd

Mike Wort / Anna Dunphy

Tel: +44 (0) 207 933 8780

avacta@walbrookpr.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGGRKMZGDZM
Date   Source Headline
1st Jul 20257:00 amRNSManagement Team Appointments
30th Jun 20253:00 pmRNSAppointment of Zeus Capital as Joint Broker
19th Jun 20257:00 amRNSNew Response in Phase 1b Trial
9th Jun 20255:15 pmRNSPosting of Annual Report and Revised Notice of AGM
6th Jun 20257:00 amRNSPreliminary Full Year 2024 Results
4th Jun 20257:00 amRNSAvacta Change in Prelim Date Part 2
28th May 20257:00 amRNSBoard appointments
27th May 20257:00 amRNSUpdate on timing of preliminary results
15th May 20257:00 amRNSNotice of Results
12th May 202512:00 pmRNS-RInvestor Webinar
8th May 20257:30 amRNSBlock Listing Application to AIM
29th Apr 20257:00 amRNSBoard change
28th Apr 20255:52 pmRNSBlock Listing Six Monthly Return
28th Apr 20257:01 amRNSAvacta presents preclinical data at AACR
28th Apr 20257:00 amRNSAvacta presents data from lead candidate at AACR
23rd Apr 20257:00 amRNSIssue of Equity and Total Voting Rights
31st Mar 20257:00 amRNSAvacta Quarterly Update
26th Mar 20257:00 amRNSAvacta Announces Presentations at AACR
25th Mar 20257:00 amRNSAvacta Completes Launch Diagnostics Sale
10th Mar 20257:00 amRNSAvacta to Present at Leerink Healthcare Conference
7th Mar 20258:40 amRNSAvacta announces data update for AVA6000
7th Mar 20257:42 amRNSAvacta to sell Launch Diagnostics
4th Feb 20257:00 amRNSAppointment of Joint Broker
21st Jan 20253:09 pmRNSIssue of Equity and Total Voting Rights
16th Jan 20257:00 amRNSAvacta Announces Data from AVA6000 Phase 1 trial
13th Jan 20257:00 amRNSAvacta Appoints Chief Financial Officer
12th Dec 20247:00 amRNSCompletion of Dose Escalation and RDE Arms
30th Oct 20247:00 amRNSR&D Spotlight focusing on pipeline advances
28th Oct 20247:00 amRNSBlock Listing Six Monthly Return
24th Oct 20247:00 amRNSAvacta Reports Pipeline Avances at EORTC
21st Oct 20244:00 pmRNSIssue of Equity and Total Voting Rights
21st Oct 20247:00 amRNSAvacta and Tempus Enter Strategic Collaboration
17th Oct 20247:00 amRNSAvacta Expands its Pipeline
15th Oct 20247:00 amRNSAvacta appoints Chief Scientific Officer
10th Oct 20247:00 amRNSAvacta Unveils Pipeline Expansion at EORTC 2024
30th Sep 20247:00 amRNSInterim Results
16th Sep 20247:00 amRNSAvacta Reported Updated Phase 1 Data of AVA6000
12th Sep 20247:00 amRNSNotice of Results
9th Sep 20247:00 amRNSAvacta to present clinical data at ESMO Congress
2nd Sep 20243:53 pmRNSDirector/PDMR Shareholdings and TVR
18th Jul 20247:00 amRNSConvertible Bond Payment
26th Jun 20242:46 pmRNSResult of AGM
26th Jun 20247:00 amRNSAGM Business Update
20th Jun 20247:00 amRNSShaun Chilton appointed Non-Executive Chairman
11th Jun 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
31st May 20247:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20247:00 amRNSSuccessful Completion of First Cohort
30th Apr 20247:01 amRNSFull Year Results
30th Apr 20247:00 amRNSBoard Change
26th Apr 20249:51 amRNSBlock listing Interim Return REPLACEMENT

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.